SAM 306.08 Page 1 of 13

United States Department of Agriculture Center for Veterinary Biologics Testing Protocol

SAM 306

Supplemental Assay Method for the Titration of Feline Calicivirus in Cell Culture

Date:	August 23, 2023
Number:	SAM 306.08
Supersedes:	SAM 306.07, October 30, 2014
Standard Requirement:	9 CFR, part 113.314
Contact:	Email: Methodsrequest.notification@usda.gov Phone: Center for Veterinary Biologics, 515-337-6100

United States Department of Agriculture Animal and Plant Health Inspection Service P. O. Box 844 Ames, IA 50010

Mention of trademark or proprietary product does not constitute a guarantee or warranty of the product by USDA and does not imply its approval to the exclusion of other products that may be suitable.

Table of Contents

- 1. Introduction
- 2. Materials
 - 2.1 Equipment/instrumentation
 - 2.2 Reagents/supplies
- **3. Preparation for the Test**
 - 3.1 Personnel qualifications/training
 - **3.2** Preparation of equipment/instrumentation
 - 3.3 Preparation of reagents/control procedures
 - **3.4 Preparation of the Test Vaccine**
- 4. **Performance of the Test**
- 5. Interpretation of the Test Results
- 6. **Report of Test Results**
- 7. References
- 8. Summary of Revisions

1. Introduction

This Supplemental Assay Method (SAM) describes an *in vitro* titration method for assaying modified-live feline calicivirus (FCV) vaccines for viral content. The method utilizes plaque forming units (PFU) in a cell culture system.

2. Materials

2.1 Equipment/instrumentation

Equivalent equipment or instrumentation may be substituted for any brand name listed below.

- **2.1.1** Syringe, self-refilling, repetitive, 2-mL
- **2.1.2** Micropipettor, 200-µl, and tips (Rainin Pipetman®)
- 2.1.3 Blender
- 2.1.4 Media bottle, borosilicate glass with screw-top lid, 1000-mL

2.1.5 Incubator, $36^{\circ}\pm 2^{\circ}$ C, high humidity, $5\% \pm 1\%$ CO₂ (Model 3158, Forma Scientific Inc.)

- 2.1.6 Water bath
- **2.1.7** Inverted light microscope (Model CK, Olympus America Inc.)
- 2.1.8 Vortex mixer (Vortex-2 Genie, Model G-560, Scientific Industries Inc.)
- **2.1.9** Pipette-aid or Handistep

2.2 Reagents/supplies

Equivalent reagents or supplies may be substituted for any brand name listed below. All reagents and supplies must be sterile.

2.2.1 FCV Positive Control virus, C-14 strain

2.2.2 Crandall feline kidney (CRFK) cell culture, free of extraneous agents as tested by title 9, *Code of Federal Regulations* (9 CFR), part 113.52

2.2.3 Minimum Essential Medium (MEM) National Centers for Animal Health (NCAH) Media #20030

- 1. 9.61 g MEM with Earles salts without bicarbonate
- **2.** 1.1 g sodium bicarbonate (NaHCO₃)
- 3. Dissolve with 900 mL deionized water (DI).

4. Add 5.0 g lactalbumin hydrolysate or edamine to 10 mL DI. Heat to $60^{\circ} \pm 2^{\circ}$ C until dissolved. Add to **Step 3** with constant mixing.

5. Q.S. to 1000 mL with DI; adjust pH to 6.8-6.9 with 2N hydrochloric acid (HCl).

- 6. Sterilize through a 0.22-µm filter.
- 7. As eptically add 50 μ g/mL gentamicin sulfate.
- 8. Store at 2° 7° C.
- **2.2.4** Growth Medium
 - 1. 900 mL of MEM
 - 2. Aseptically add:
 - **a.** 100 mL gamma-irradiated fetal bovine serum (FBS)
 - **b.** 10 mL L-glutamine (200 mM)
 - **3.** Store at 2° 7° C.

2.2.5 2X Medium

- 1. 19.22 g MEM with Earles salts without bicarbonate
- 2. 2.2 g NaHCO₃
- **3.** Dissolve with 900 mL DI.

4. Add 5.0 g lactalbumin hydrolysate or edamine to 10 mL DI. Heat to $60^{\circ}\pm 2^{\circ}$ C until dissolved. Add to **Step 3** with constant mixing.

- 5. Q.S. to 1000 mL with DI and adjust pH to 6.8-6.9 with 2N HCl.
- 6. Sterilize through a 0.22-µm filter.
- 7. Store at 2° 7° C.

8. On the day of test initiation and prior to preparing the Overlay Medium, aseptically add 100 μ g/mL gentamicin sulfate.

- **2.2.6** 2% Tragacanth Gum (Trag)
 - 1. 20 g Trag
 - 2. 1000 mL DI

3. Add small amounts of Trag at a time and vigorously mix with a blender set on high.

- 4. Pour 500 mL into individual glass 1000-mL media bottles.
- 5. Sterilize by autoclaving at 15 psi, $121^{\circ} \pm 2^{\circ}$ C for 35 ± 5 minutes.
- 6. Store at 2° 7° C.
- 2.2.7 7.5% Sodium Bicarbonate
 - 1. 7.5 g NaHCO₃
 - **2.** Q.S. to 100 mL with DI.
 - **3.** Sterilize by autoclaving at 15 psi, $121^{\circ} \pm 2^{\circ}$ C for 30 ± 10 minutes.
 - 4. Store at 2° 7° C.
- **2.2.8** 70% Ethyl Alcohol (NCAH Media #30184)
 - **1.** 73 mL ethyl alcohol (95% [195 proof])
 - **2.** 27 mL DI
 - **3.** Store at room temperature.

- **2.2.9** Crystal Violet Stain (NCAH Media #30012)
 - 1. 7.5 g crystal violet
 - 2. 50 mL 70% Ethyl Alcohol
 - 3. Dissolve crystal violet in alcohol; add remaining ingredients.
 - 4. 250 mL formaldehyde

Note: According to 29 CFR 1910.1048, precautions for the use of formaldehyde are as follows: Toxic by inhalation and if swallowed. Irritating to the eyes, respiratory system and the skin. May cause sensitization by inhalation or by skin contact. Risk of serious damage to eyes. Potential cancer hazard; repeated or prolonged exposure increases the risk.

- 5. Q.S. to 1000 mL with DI.
- 6. Filter through Whatman[®] #1 filter paper.
- 7. Store at room temperature.
- **2.2.10** Tissue culture plates, 4-well
- 2.2.11 Polystyrene tubes, 12 x 75-mm
- **2.2.12** Pipettes, 25-mL
- 2.2.13 Needles, 18-gauge x 1 1/2-inch
- 2.2.14 Syringes (tuberculin), 1-mL

3. Preparation for the Test

3.1 Personnel qualifications/training

Personnel must have experience in the preparation and maintenance of cell culture as well as in the propagation and maintenance of animal viruses and the quantitation of virus infectivity by plaque formation.

3.2 Preparation of equipment/instrumentation

On the day of test initiation, set a water bath at $36^{\circ} \pm 2^{\circ}$ C.

3.3 Preparation of reagents/control procedures

3.3.1 Preparation of CRFK tissue culture plates (Test Plates)

Cells are prepared from healthy, confluent CRFK cell cultures that are maintained by passing every 3 to 4 days. Two days prior to test initiation, add 8.0 mL/well of approximately $10^{5.0}$ to $10^{5.3}$ cells/mL suspended in Growth Medium into all wells of a 4-well tissue culture plate. Prepare one Test Plate for the FCV Positive Control and one for each Test Vaccine. Incubate at $36^{\circ}\pm 2^{\circ}$ C in a CO₂ incubator.

3.3.2 Preparation of FCV Positive Control

1. On the day of test initiation, rapidly thaw a vial of current FCV Positive Control virus in the water bath.

2. Dispense 1.8 mL of MEM into sufficient 12 x 75-mm polystyrene tubes to bracket the expected endpoint appropriately label (e.g., 9 tubes, labeled 10^{-1} through 10^{-9} , respectively).

3. Transfer 200 μ L of the FCV Positive Control virus to the tube labeled 10⁻¹; mix by vortexing.

4. Using a new pipette tip, transfer 200 μ L from the 10⁻¹-labeled tube to the 10⁻² tube; mix by vortexing.

5. Repeat Section 3.3.2(4) for each of the subsequent dilutions, transferring 200 μ L of the previous dilution to the next dilution tube until the tenfold dilution series is completed.

3.3.3 Overlay Medium Preparation

On the day of test initiation, prepare approximately 35 mL per plate of Overlay Medium. Volumes listed are for 1 liter of overlay medium.

- 1. Aseptically add to 500 mL of 2X Medium:
 - **a.** 10% gamma-irradiated FBS
 - **b.** 10 mL of 7.5% Sodium Bicarbonate

- c. $50 \mu g/mL$ gentamicin sulfate
- **d.** 500 mL of 2% Trag
- 2. Mix and warm the Overlay Medium in a $36^{\circ} \pm 2^{\circ}$ C water bath for 60 ± 10 minutes prior to performing the procedure in Section 4.5.

3.4 Preparation of the Test Vaccine

3.4.1 The initial test will be with a single vial (a single sample from one vial). On the day of test initiation, using a 1.0-mL syringe and an 18-gauge x 1 1/2-inch needle, rehydrate a vial of the Test Vaccine with the provided diluent by transferring 1.0 mL for a 1-mL-dose vaccine, 0.5 mL for a 1/2-mL-dose vaccine, etc., into the vial containing the lyophilized Test Vaccine; mix by vortexing. Incubate for 15 ± 5 minutes at room temperature.

3.4.2 Dispense 1.8 mL MEM into each of 6, 12×75 -mm polystyrene tubes labeled 10^{-1} through 10^{-6} .

3.4.3 Transfer 200 μ L of the Test Vaccine to the tube labeled 10⁻¹; mix by vortexing.

3.4.4 Using a new pipette tip, transfer 200 μ L from the tube labeled 10⁻¹ to the 10⁻² tube; mix by vortexing.

3.4.5 Repeat Section 3.4.4 for each of the subsequent dilutions, transferring 200 μ L of the previous dilution to the next dilution tube until the tenfold dilution series is completed.

4. **Performance of the Test**

4.1 On the day of test initiation, label the Test Plates and remove the Growth Medium.

Note: Presence of confluent cells is necessary in order to distinguish plaques due to infection by FRV. If cells are not confluent at two days incubation, start of the test may be delayed an additional day in order to obtain confluency.

4.2 Inoculate one well/dilution with 200 μ L from dilutions 10⁻⁶ through 10⁻³ of the Test Vaccine, starting with the highest dilution (most dilute). Inoculate one well/dilution from dilutions 10⁻⁹ through 10⁻⁷ of the FCV Positive Control. Change tips between each unique sample (i.e., each Test Vaccine), but tip changes are not necessary between each

dilution in a series when pipetting from the most dilute to the most concentrated (e.g., 10^{-6} through 10^{-3}). Gently rotate the plates to evenly disperse the inoculum.

4.3 One uninoculated well on a Test Plate serves as a negative cell control.

4.4 Incubate the inoculated Test Plates at $36^{\circ} \pm 2^{\circ}$ C for 75 ± 15 minutes in a CO₂ incubator. To evenly disperse the inoculum, gently rotate the plates at intervals of 25 ± 5 minutes.

4.5 Add 8 mL/well of the Overlay Medium to the plates with a 25-mL pipette. Discard any unused, warmed Overlay Medium.

4.6 Incubate the Test Plates undisturbed at $36^{\circ} \pm 2^{\circ}$ C in a CO₂ incubator for 4 days \pm 1 day.

4.7 After incubation, without removing the Overlay Medium, pipette 5 mL of the Crystal Violet Stain (Section 2.2.9) into each well of the Test Plates with a 25-mL pipette; mix by gentle rotation. Note the precaution statement in Section 2.2.9(4).

4.8 Allow Test Plates to incubate at room temperature 25 ± 5 minutes.

4.9 Wash the Overlay Medium and the Crystal Violet Stain from the cell monolayers by dipping each plate several times in a container overflowing with running water from the cold water tap until the water is clear. Allow to air dry.

4.10 Count the number of FCV plaques for each well and record observations. If FRV and FCV plaques are counted together in a combination vaccine, the FCV plaques will contrast markedly from FRV. The FRV plaques are visible as small, clear plaques approximately 1 mm in diameter with distinct edges. The FCV plaques are large, clear circular areas (averaging 3 to 4 mm in diameter) with fuzzy edges. If the plaques are not distinguishable by size, use an inverted light microscope with 100X magnification to differentiate the plaque edges.

4.11 Record results as the number of FCV plaques for each dilution of a Test Vaccine and the FCV Positive Control.

4.12 Calculate the FCV titers of the Test Vaccine and the FCV Positive Control from the dilutions with plaque counts containing 10-100 plaques. The titer may be expressed as PFU per dose of vaccine.

Example:

During the titration of a Test FCV vaccine, the plaque count obtained at dilution 10⁻³ was 65. Calculation of the titer of this vaccine is done according to the following formula:

Test Vaccine Titer = X + p, where

 $\mathbf{X} = \text{Log}_{10}$ of plaque count $\mathbf{p} = \text{Log}_{10}$ of dilution counted

In the above example:

 Log_{10} of plaque count (65)= 1.8 Log_{10} of dilution counted (10⁻³)= 3.0

FCV Test Vaccine Titer = 1.8 + 3.0 = 4.8

Adjust the titer to the recommend Test Vaccine dose as follows:

A. Divide the Test Vaccine Dose by the Inoculation Dose

Test Vaccine Dose = manufacturer's recommended vaccination dose (for this test FCV vaccine, the recommended dose is 1 mL)

Inoculation Dose = amount of diluted Test Vaccine added to each well of the Test Plate (for this test FCV vaccine, the inoculation dose is 0.2 mL)

 $\frac{1 \text{ mL dose}}{0.2 \text{ mL inoculum}} = 5$

B. Calculate log₁₀ of value in **A** and add it to the **Test Vaccine Titer** as illustrated below:

Log of 5 = 0.7

FCV Test Vaccine Titer = 4.8 + 0.7 = 5.5

Therefore, the titer of the FCV Test Vaccine is $10^{5.5}$ PFU₅₀/mL.

4.13 One plaque represents a single infective unit (IU), whereas one, 50% tissue culture infective dose (TCID₅₀) is statistically equivalent to a theoretical 0.69 IU. A TCID₅₀ endpoint per dose will be 1.44 times those expressed as PFU per dose. Therefore, to express a PFU titer as a TCID₅₀ titer, multiply the plaque count by 1.44. In the example above, multiply 65 times 1.44 resulting in 93.6. Convert 93.6 to log₁₀ resulting in 1.97.

Add the log for the dilution counted (3) and the conversion factor for dose (0.7) which results in a log_{10} TCID₅₀/mL of 5.67. In practical use, 0.16 (the log of 1.44) may be added to the log_{10} value of the PFU titer per mL to convert to TCID₅₀/mL. From the above example, the titer of the Test Vaccine is $10^{5.66}$ TCID₅₀/mL.

5. Interpretation of the Test Results

5.1 Validity requirements

5.1.1 The calculated titer of the FCV Positive Control must fall within plus or minus 2 standard deviations (\pm 2 SD) of its mean titer, as established from a minimum of 10 previously determined titers.

5.1.2 The uninoculated cell control cannot exhibit any plaques, cytopathic effects (CPE), or cloudy media that would indicate any contamination.

5.1.3 For endpoint determination, only those tenfold dilutions of the Test Vaccine and the FCV Positive Control inducing 10 to 100 plaques are included in the plaque counts.

5.2 If the validity requirements are not met, then the assay is considered a **NO TEST** and can be retested without prejudice.

5.3 If the validity requirements are met and the titer of the Test Vaccine is greater than or equal to the titer contained in the Animal and Plant Health Inspection Service (APHIS) filed Outline of Production for the product under test, the Test Vaccine is considered **SATISFACTORY**.

5.4 In a valid test, if the titer of the Test Vaccine is less than the titer contained in the APHIS filed Outline of Production for the product under test, the Test Vaccine may be retested in accordance with title 9, *Code of Federal Regulations*, part 113.8.b.

6. **Report of Test Results**

Report results as PFU₅₀ or TCID₅₀ per dose of Test Vaccine.

7. References

7.1 Title 9, *Code of Federal Regulations*, parts 113.8(b) and 113.314, U.S. Government Printing Office, Washington, DC.

7.2 Title 29, *Code of Federal Regulations*, part 1910.1048, U.S. Government Printing Office, Washington, DC.

7.3 Cottral, GE. *Manual of standardized methods for veterinary microbiology*. Comstock Publishing Associates. Ithaca, New York, 1978, pg. 731.

7.4 Davis, Dulbecco, Eisen, Ginsberg, ed. *Microbiology including Immunology and Molecular Genetics*, 3rd ed. Harper and Row, Hagertown, 1980, pg. 880.

8. Summary of Revisions

Version .08

• The coversheet and contact information have been updated.

Version .07

• The Contact information has been updated; however, the Virology Section has elected to keep the same next review date for the document.

Version .06

• The contact information has been updated.

Version .05

- The Contact information has been updated.
- FCV Positive Control virus, C-14 strain is no longer available from the CVB and all references to it have been removed from the document.
- References to NVSL have been changed to NCAH throughout the document.

Version .04

- The Contact has been changed from Victor Becerra to Alethea Fry.
- **2.2.9:** A precautionary statement for use of formaldehyde has been added.
- **4.13:** Conversion from PFU₅₀/mL to TCID₅₀/mL has been clarified.
- Use of reference control terminology has been changed to positive control throughout the document.

Version .03

This document was revised to clarify the practices currently in use at the Center for Veterinary Biologics and to provide additional detail. While no significant changes were made that impact the outcome of the test, the following changes were made to the document:

- **1.2** "Key Words" has been deleted.
- **2.2.3.2** The amount of sodium bicarbonate (NaHCO₂) has been changed from 2.2g to 1.1g.
- **2.2.5.8** 50 μ g/ml gentamicin sulfate has been changed to 100 μ g/ml and the use of penicillin and streptomycin has been deleted.
- 4.6 Ninety-six hours has been changed to 4 days ± 1 day.
- **4.12** The determination of virus titer for each Test Vaccine has been rewritten to correct errors in calculations using the example given.
- 5.1.3 The endpoint determination of plaques has been clarified.
- The refrigeration temperatures have been changed from $4^\circ \pm 2^\circ C$ to $2^\circ 7^\circ C$. This reflects the parameters established and monitored by the Rees system.
- "Test Serial" has been changed to "Test Vaccine" throughout the document.
- "Reference Reagent Sheet" has been changed to "Reagent Data Sheet" throughout the document.
- The footnotes have been deleted with any pertinent references now noted next to the individual items.